Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Milei Threatens Falkland Oil Firms With Sanctions 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
BURLINGTON, Mass., Feb. 28, 2018 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, Florida. Dr. Clayman is scheduled to present at 8:05 a.m Eastern Time on Tuesday, March 6, 2018. Investors can access the live webcast and subsequent archived recording of the presentation by visiting the Flexion website at http://ir.flexiontherapeutics.com
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of The Boston Business Journal's 2017 Best Places to Work and one of the Top Places to Work in Massachusetts by The Boston Globe.
Corporate Contact:
Scott Young
Vice President, Corporate Communications and Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]
